BofA/Merrill Lynch Downgrades Biogen (BIIB) to Neutral
Tweet Send to a FriendGet Alerts BIIB Hot Sheet
Price: $232.62 -0.19%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Trade BIIB Now!
BofA/Merrill Lynch downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $143.88 yesterday, with a 52 week range of $114.53-$157.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $143.88 yesterday, with a 52 week range of $114.53-$157.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO
- Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
- Vivus (VVUS) Sees Upside on Icahn Connection
Create E-mail Alert Related Categories
DowngradesRelated Entities
Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
